Concepts and Controversies in Haemostasis and Thrombosis Associated with Liver Disease: Proceedings of the 7th International Coagulation in Liver Disease Conference
Year: 2018
Type: article
Abstract: Introduction Patients with acute and chronic liver disease frequently acquire unique changes in haemodynamic and haemostatic pathways that may result in life-threatening bleeding and thrombosis. Additionally, activation of haemostatic pathways may play a role in disease progression through parenchymal extinction, organ atrophy, recruitment of inflammatory cells and activation of stellate cells. In the setting of a previously entrenched set of clinical perceptions, the slowly evolving evidence-based paradigms of haemostasis in cirrhosis are now more carefully scrutinized. The 7th International Conference on Coagulation in Liver Disease (held biennially since 2005) met in October of 2017 in Rome, Italy, to discuss and debate important topics in this field. This document provides a statement-based thematic summary of the meeting presented here amid a framework of the most current evidence. The review of the literature, preparation of the document and presentation of each summary statement below are based on systematic approaches used in published guidance documents.[ 1 ] In particular, recognition of the potential disconnect between existing evidence and actual practice, we utilized a questionnaire and real-time poll of the conference attendees to compare actual clinical practice to the evidence-based support for each statement. The final section summarizes the results of the most salient results of the poll. Laboratory Testing of the Coagulation System in Patients with Cirrhosis 1. Traditional coagulation measures, including pro-thrombin time (PT), activated partial thromboplastin time (aPTT), international normalized ratio (INR) and bleeding time (BT) do not measure bleeding risk in cirrhosis. Conventional in vitro tests of the coagulation system are of limited value in estimating haemostatic competency in cirrhosis and current literature emphasizes these limitations when compared with global assays of coagulation.[ 2 ] [ 3 ] [ 4 ] [ 5 ] PT/INR, aPTT and BT are generally prolonged in patients with cirrhosis in direct relationship to the degree of hepatic decompensation. While useful for predicting prognosis in chronic liver disease, these tests do not predict bleeding or thrombosis in patients with chronic liver disease. For the PT/INR and aPTT, a trigger reagent (tissue factor for extrinsic pathway or kaolin for the intrinsic pathway), phospholipids and calcium are added to patient plasma in a test tube and the time to the formation of fibrin is recorded. The PT/INR test performs poorly in assessing coagulation capacity in patients with liver disease[ 6 ] and suffers from high inter-laboratory variability.[ 7 ] [ 8 ] The PT/INR measures only pro-thrombotic pathways without measuring counter-balancing anticoagulation (AC) pathways including protein C. Numerous studies and clinical experience now clearly demonstrate that these tests do not measure in vivo activity of the coagulation system in cirrhosis.[ 9 ] [ 10 ] [ 11 ] [ 12 ] [ 13 ] 2. Platelet count alone provides an incomplete guide to bleeding risk in cirrhosis. However, values below 50,000/μL may be associated with higher risk of bleeding. Thrombocytopenia is common in patients with advanced cirrhosis and indirectly correlates with the degree of portal hypertension and hepatic decompensation.[ 14 ] In vitro evidence indicates that platelet-dependent thrombin generation is preserved in patients with cirrhosis with platelet levels 56,000/μL or greater.[ 15 ] Notably, however, other important aspects of platelet function are not assessed by thrombin generation assay (TGA). Severe thrombocytopenia is associated with procedural-related bleeding events in some, but not all studies.[ 16 ] [ 17 ] While there is no evidence that prophylactic platelet transfusion improves haemostatic potential,[ 18 ] current guidelines and expert opinion recommend consideration of platelet transfusion prior to high-risk procedures or when active bleeding is encountered in patients with platelet counts below 50,000/μL.[ 4 ] [ 19 ] A notable exception is liver transplant surgery, in which platelet counts below 50,000/μl are accepted by many centres. 3. Global viscoelastic tests (VETs) provide a more physiologic assessment of coagulation, VETs are not standardized in patients with liver disease and do not appear to predict bleeding or thrombosis. Application of VETs in patients with liver disease remains controversial. VETs measure clot strength and integrity in whole blood under low shear conditions, attempting to more closely recreate the environment in vivo during clot formation.[ 20 ] VETs are considered point-of-care tests and provide the clinician with information regarding the kinetics of clot formation and strength of the clot with the ability to distinguish contributions from fibrinogen, platelets and the fibrinolytic system. VETs are most extensively studied in patients with cirrhosis undergoing liver transplantation.[ 20 ] [ 21 ] [ 22 ] [ 23 ] [ 24 ] [ 25 ] [ 26 ] [ 27 ] [ 28 ] [ 29 ] [ 30 ] [ 31 ] [ 32 ] [ 33 ] [ 34 ] [ 35 ] [ 36 ] [ 37 ] [ 38 ] [ 39 ] More recently VETs have been employed to examine the haemostatic system in a wide variety of patients with liver disease, including well-compensated patients,[ 40 ] [ 41 ] [ 42 ] patients with acute liver failure[ 43 ] and in acutely ill patients with liver disease.[ 44 ] [ 45 ] [ 46 ] A recent randomized control trial compared transfusion-directed prophylactic therapy in patients with cirrhosis undergoing procedures using VETs as a guide versus standard coagulation tests.[ 47 ] While significantly less blood product was used in the group undergoing VETs screening, the low rate of bleeding events, lack of control arm and inclusion of relatively low risk procedures significantly limits conclusions from these data.[ 48 ] Specific nuances of VETs such as test performance without stimulators (‘native’ VETs) and optimal duration of test remain uncertain in cirrhosis. 4. TGA provides a more comprehensive assessment of the haemostatic system in cirrhosis. However, the clinical utility of TGA in patients with cirrhosis is unexplored with current use confined mainly to research. TGA is a valuable research tool that has led to important insights in liver disease and coagulation.[ 9 ] [ 10 ] [ 11 ] [ 12 ] [ 13 ] [ 15 ] [ 18 ] [ 49 ] [ 50 ] [ 51 ] [ 52 ] [ 53 ] [ 54 ] It measures the rate of production and decay of thrombin after of a (tissue factor and ] [ ] [ ] [ ] the of for activation of protein the integrity of the protein system is that thrombin generation is preserved in cirrhosis prolonged coagulation assays to protein 10 ] [ 13 ] and of TGA is incomplete and clinical use is not and of a point-of-care whole blood thrombin generation test are in with the for clinical 52 ] [ ] [ ] tests of are of limited value in cirrhosis and clinical is therapy the of in cirrhosis is with limited and ] [ ] [ ] [ ] [ ] on clinical assessment and therapy are recommend the and of in Patients with The fibrinolytic system clot and and is in cirrhosis. a of fibrin by to bleeding and has been a clinical of cirrhosis for a ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] the or coagulation and the of bleeding in cirrhosis but from coagulation ] This was in a clinical evidence of was in a of cirrhosis but in only of ] However, the results of studies which the role of liver thrombin has in regarding the clinical of ] [ ] studies have to the and of bleeding or bleeding and of ] [ ] the other studies have fibrinolytic capacity in cirrhosis ] a system more to clot ] and the ] have been as of clot and of in Patients with Cirrhosis bleeding is common in cirrhosis but of 16 ] For many the PT/INR as a for estimating bleeding risk in cirrhosis. However, use of the and as a clinical is not or by evidence. have this for many This is by the limited between the clinician the and the This to of the trial of and which not However, the has since ] This now for more based on recent of patient is as clinical such as acute ] or ] may bleeding risk in clinical Global such as have potential in patients with cirrhosis and active of may to an patients higher risk to ] [ ] clinical studies bleeding are to provide with to of plasma and platelet is for high-risk procedures [ 1 and is for high risk the the of 1 of a ] risk procedures risk procedures risk procedures or and or liver with or of organ or or a is here based on degree of and potential clinical but risk be by clinician the test and measures are to the nuances of a there are that platelet and the of correlates to has not been of low levels bleeding ] is limited regarding measure as a guide to prophylactic measures and is mainly from bleeding risk many do not low or platelets prior to liver and a clinical trial has to demonstrate a of ] the limitations and lack of with current in the these are considered to be useful in predicting bleeding in cirrhosis for low or risk procedures [ 1 is generally not However, approaches are The most with whole blood VETs as or has been the of haemostatic in cirrhosis with evidence that haemostatic support with blood is not or platelet ] [ ] the of studies in this have a control arm which limits of the risk in patients without this we a poll to actual current practice in potential to The most important to is that prophylactic measures PT/INR bleeding risk by the without haemostatic recognition of the bleeding risk and the limitations of by that procedures and other patient Specific Platelet transfusion prior to high-risk procedures or with active bleeding has a in vitro but high the may have a role in regarding bleeding risk and The in the literature the of haemostasis in cirrhosis and patients undergoing liver transplant bleeding in was closely to platelet levels 16 ] bleeding risk was higher in a of cirrhosis patients undergoing when platelets ] Platelet levels an of bleeding ill cirrhosis patients in the ] the other bleeding in cirrhosis was not by platelet levels in ] and the risk of bleeding has been ] [ ] which may platelet such as factor ] activated ] and ] may be which the bleeding risk to may to platelet ] [ ] [ ] of platelet in cirrhosis is and the of platelet transfusion prior to high-risk procedures is more to or an actual is an that remains More studies which clinical with the current of the In and such as or other procedures with or high are an to platelets prior to for a to with with of risk of portal thrombosis have for these ] [ ] [ ] However, are in such as and which appear to platelets to a associated with thrombin production without thrombosis ] [ ] The use of in patients with cirrhosis a and not appear to significantly risk of bleeding. or has been to be as as blood in cirrhosis patients undergoing ] Notably, bleeding was in the of actual and no control arm without was studies no in liver in patients with chronic and with partial ] [ ] [ ] A recent lack of in cirrhosis patients a of compared with a control group of patients with ] the of the for to more the utility of prophylactic pro-thrombin and factor may have a role in of bleeding in patients with cirrhosis in clinical but the utility of these is The regarding in clinical bleeding is associated with of levels are associated with more ] based on limited levels below in active bleeding patients with cirrhosis have However, remains to be in cirrhosis.[ ] has a product in and by and plasma and the in 10 to 20 In are from a of plasma which and ] The low of and lack of for use in cirrhosis. in vitro a in haemostasis in cirrhosis.[ ] However, clinical studies are to the which limits have been studied in cirrhosis for 40 ] [ ] However, is to therapy as the is based on factor of the on and are that may be in but ] A is 25 to 30 of factor of The low for patients is to and in the risk of thrombosis has mainly been studied in cirrhosis and bleeding. was in patients with as an in ] [ ] However, the use of this as a in in cirrhosis remains by randomized ] In and bleeding in cirrhosis use of of patients with to and of are that the on to fibrin and or and ] [ ] be or are to be significantly pro-thrombotic based on studies in of versus ] of the of there is risk of ] and the high of the in A is a that to to activity and platelet The the for blood transfusion in liver ] but in that ] and was associated with in to in clinical ] and for in Patients with Cirrhosis Patients with advanced cirrhosis and low portal blood 15 are the risk to portal or thrombosis. The risk for in cirrhosis the of liver disease and hepatic decompensation. The of is in cirrhosis patients as to 8 to in liver transplant ] [ ] and to in patients with ] the to blood and portal is the most ] [ ] blood is to of liver disease as by the ] and 10 are associated with ] Patients with are risk for but in be to in cirrhosis.[ ] that cirrhosis may have in which patients In particular, may be an risk factor for events, including in patients with cirrhosis.[ ] [ ] [ ] The of a is an risk for as a result of a and ] Patients with cirrhosis and portal hypertension be for of 6 with In a systematic review that was associated with in patients with cirrhosis.[ ] by a recent that was associated with more portal hypertension and higher ] studies that is associated with to ] [ ] [ ] However, a trial of in A and cirrhosis that was not an of or hepatic decompensation.[ ] studies are to the of on patients with cirrhosis. patients with cirrhosis for 6 assessment of the be with without and is Patients with cirrhosis for liver be 6 with for In the of higher to after liver transplantation.[ ] [ ] [ ] [ ] [ ] [ ] [ ] However, studies that the of may not the for patient ] [ ] studies are to compare to the of in this and The ability of a to a physiologic for portal to the is the most important factor in predicting and to the degree of ] [ ] [ ] of prior to liver in and for potential therapy to the of higher may patients that are not for of the is a high in transplant ] [ ] for has a higher rate after recognition and is Patients with cirrhosis with by be assessed with to and the of While is generally the to cirrhosis patients for is limited by in and in to and ] [ ] this has a high value ] and have in the of on and are in the of for and other ] [ ] [ ] are of are in clinical ] [ ] [ ] the system remains the most frequently utilized system in clinical ] Testing for and in cirrhosis be considered in patients with on an but is not is in as many as of patients with cirrhosis and ] have more of the pro-thrombin in cirrhosis patients with ] [ ] risk may in patients with cirrhosis. The is in in patients with cirrhosis and ] a is with a is for protein protein or may to however, these are to to liver 5 ] [ 11 ] [ ] of in Patients with Cirrhosis to patients be assessed for portal or bleeding of bleeding risk and of therapy is when but not in this to recent active and to Severe thrombocytopenia 50 10 9 may be of bleeding events in cirrhosis patients with for and consideration be to this ] to patients to for the of ] high-risk are or therapy with be utilized as ] [ ] to be a and in patients with cirrhosis and thrombosis. in patients with cirrhosis and thrombosis is an of in ] [ ] [ ] in are the of which have been low and ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] and patients are in these patient ] [ ] of bleeding from 5 to and bleeding from 1 to but of bleeding are not A recent for patients with cirrhosis and and a bleeding rate of all bleeding events and of for or ] the of not of bleeding events in patients with cirrhosis.[ ] While bleeding appear is important to the high rate of the and lack of randomized be when patients with cirrhosis for with in patients with more advanced cirrhosis and approaches on a are studies the or of is to the of patient and variety of of In are and from 42 to in of a partial or a of the ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] associated with therapy of the recent time of of 6 and the degree of ] [ ] [ ] after therapy for clot from 27 to ] [ ] or direct be considered for therapy in patients with cirrhosis A and Patients with cirrhosis are no considered and evidence clearly indicates risk of and thrombosis in this patients with liver disease have been from clinical of these current paradigms are based on and experience in studies in cirrhosis have been a to therapy many through of which for the function of protein and protein Patients with liver a when using as the is to hepatic the is use of in patients for transplant the and organ for of and to through clinical use many low and in liver disease the of with uncertain levels and an in bleeding ] is a which through to factor and the production of is the most studied in patients with cirrhosis and and for of However, studies in cirrhosis are generally and with in and and remain a to therapy of to is controversial. assays are used for patients on however, these assays be in liver disease.[ ] [ ] [ ] TGA may a more tool in cirrhosis to however, these are not 50 ] In vitro studies using TGA that the of may be in patients with cirrhosis.[ 50 ] [ ] While no for of the of is partial of be with in ] to coagulation factor and factor are now used in patients without liver function with and However, remain in patients with cirrhosis with experience limited to in vitro studies and ] [ ] [ ] [ ] [ ] [ ] The to bleeding ] In vitro that may have in patients with cirrhosis on the degree of hepatic ] [ ] [ ] Notably, cirrhosis patients have been from clinical and on is limited to in vitro studies with in and cirrhosis in the only has an direct ] [ ] A recent of prior to liver without bleeding or thrombosis the use of this ] and as of factor are potential ] [ ] may be considered for in the setting of however, the the of compared with direct ] [ ] of in patients with cirrhosis be to well-compensated patients A or with platelet count and with is Liver transplant with be considered for may The for of acute and chronic in patients with cirrhosis remains controversial. The of literature on the and therapy of in the of liver transplantation.[ ] [ ] of liver are limited and the and of therapy are more to 2 and is associated with higher and in patients undergoing liver transplantation.[ ] [ ] [ ] [ ] [ ] [ ] [ ] physiologic blood through the is ] The ability to physiologic to the is generally on the of the prior to Patients with low and have to patients without more advanced 2 or of the or thrombosis prior to is Liver transplant with with or without the be for with While of with may hepatic ] a recent is not to liver disease ] Patients with acute portal hypertension and progression of thrombosis may be a risk for or are however, patients may from therapy for acute with 2 or higher therapy be considered on an after and is a of acute and chronic in patients with cirrhosis for portal the of in patients with cirrhosis was a for However, more recent experience that is and for the of when in the of portal hypertension or of the ] [ ] [ ] of are to from and from to on the ] [ ] [ ] that alone may be for and no chronic is to ] [ ] [ ] Patients with chronic considered potential transplant may from as are now of the use of in this to the portal system as a to liver transplantation.[ ] [ ] [ ] Disease in Patients with Cirrhosis patients with cirrhosis are risk for ill patients are risk of with an rate of 4 to ] However, studies the of and with have generally patients with cirrhosis. studies that patients with cirrhosis are risk to ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] patients with cirrhosis are an risk to and studies that is in this ] [ ] [ ] The was as a risk assessment to predict the of in ] guidelines for of in patients on the use of the to distinguish between low risk of and high risk of ] The has been studied in a in patients with cirrhosis and was to be of of ] The risk assessment was in a of which patients with liver disease and risk patients in of thrombosis and bleeding ] In high-risk cirrhosis patients without with or be remains risk assessment and use of is in ] Patients with cirrhosis are to be higher risk of bleeding and do not ] patients with cirrhosis for and relatively low of bleeding patients with bleeding ] studies that use of and with low of ] [ ] not between patients with cirrhosis with or compared with patients with cirrhosis not with ] was with of procedural-related bleeding. While no current studies for in the cirrhosis prophylactic was and of in a of cirrhosis ] to the of studies in patients with cirrhosis current are limited to from studies in other without and expert Cirrhosis patients with be with therapy with or direct be The of studies and in in patients with cirrhosis have been in patients with the of in Patients with studies have of in patients with cirrhosis with 17 patients with cirrhosis and with and high bleeding on ] of the 17 patients a as bleeding blood on However, from this the of the employed or the of each patient was Numerous studies since have the of and in patients with cirrhosis for and ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] In a recent patients with cirrhosis with versus or 16 of the 39 patients for ] was no between in bleeding events in the group in the A compared and for in a of 20 patients in the group and 12 in the ] between was not assessed in The of and in be from studies in However, the of therapy in in cirrhosis is not studied and the of therapy and of are from guidelines for of ] to the bleeding risk be with and an high-risk are consideration of or therapy is prior to in the of in Patients with of and of of the 2017 7th International Coagulation in Liver Disease Conference and In recognition of the limitations of existing and the between evidence-based and actual practice, we an poll during the conference and a more poll of to the The to actual clinical as to in this field. attendees the poll rate was and 2 and prior to procedures and platelets have as important of bleeding However, are now to these and to other potential of bleeding Global coagulation tests research is to to and use global assays of such as thrombin generation tests and VETs and in and cirrhosis with a to standard this in cirrhosis In most clearly after liver are now to examine the and risk of anticoagulation for the of in all patients with cirrhosis transplant with a on clinical aspects to risk to and of therapy and disease progression activation of and thrombosis in parenchymal may to and hepatic but more studies and clinical studies in are in cirrhosis studies are to examine the utility of current risk in cirrhosis patients with a of of the and of in cirrhosis in cirrhosis The and of all and direct in patients with and cirrhosis is poorly studies are now to guide therapy with these portal thrombin generation viscoelastic all of coagulation was for most However, was when the of of coagulation in poorly predicting haemostasis the in use and the lack of utility of in or bleeding of the most the of plasma and platelet count assessment and of that these tests are useful in high-risk but that these not in or is a with that cirrhosis patients are risk of but less regarding the use of with was that a was that control of was prior to the and of was generally high for most attendees that cirrhosis patients be with 6 for and that patients for liver transplant be assessed 3 with of results with a prior to consideration of was however, with to the utility of a as many not in of of and duration of only more of with compared with of as a to to of was less with only with the prior of actual practice and 5 ] this 2017 on the limitations of measures of bleeding risk assessment using but of a existing are the of in cirrhosis and more to in the setting of and there is as to the utility of and platelet measures as of bleeding risk prior to high-risk However, the utility of more of such as remain uncertain in the setting of in cirrhosis. Notably, in the a is in the of patients with and these tests in patients with is on the by ] While in of the of the coagulation system in liver disease have been the research be to the 2
Source: Thrombosis and Haemostasis
Authors: N. M. Intagliata, C. K. Argo, J. G. Stine, T. Lisman, S. H. Caldwell, F. Violi, On behalf of the faculty of the 7th International Coagulation in Liver Disease
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Keywords: hemostasis, thrombosis, liver disease, liver cirrhosis, bleeding risk, coagulation tests, global coagulation assays, prothrombin time, activated partial thromboplastin time, international normalized ratio, bleeding time, hepatic decompensation, portal hypertension, portal vein thrombosis, variceal bleeding, liver transplantation, anticoagulation
Open Access status: hybrid
OpenAlex ID: W2886985238
